View Clinical Trials Below

Clinical Trials for Lung Cancer Treatments

Every year, there are more than 200,000 new cases of lung cancer in the U.S. The good news is that over the past decade, lung cancer death rates have been dropping thanks to improvements in treatments made possible by clinical trials. At Regional Cancer Care Associates, we conduct more than 300 advanced clinical trials. To see if a lung cancer clinical trial is right for you, contact RCCA at 201-669-4706.

Defining Clinical Trial

Clinical trials are research studies that test the safety and effectiveness of new medical approaches to prevent, detect, diagnose and cure certain diseases. When it comes to lung cancer, these studies provide data that help give medical professionals insight into new drugs, treatment techniques and devices and their ability to treat cancer patients. Before being offered as a clinical trial, the therapies must undergo a lengthy research process in a laboratory. When they finally become available to the medical community, these treatments will be meticulously designed. Prior to giving consent for a clinical trial, patients will receive in-depth information about the various aspects of the treatment, including all possible risks and benefits.

The Clinical Trial Advantage

Lung cancer treatments are constantly being developed, but before they can be approved, they must be tested for human use. As a participant in a clinical trial, you’ll receive access to innovative treatments that have yet to hit the market. Besides presenting you with cutting-edge medical therapies, clinical trials give you the chance to make a difference in the future of lung cancer care. Clinical trials are also considered an affordable option for lung cancer patients. In fact, all cost of care is covered by the sponsoring company. At RCCA specifically, we always put the safety and wellbeing of our clinical trial participants first – an institutional review board and scientific experts will closely monitor trial protocols to ensure strict regulations are enforced throughout the process.

Lung Cancer Clinical Trials at RCCA

Want more information about enrolling in a lung cancer clinical trial? Make an appointment at your nearest RCCA location to speak with a cancer care specialist about your clinical trial eligibility.
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Read more
A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Read more
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Read more